# Lakefront Biotherapeutics NV: Form 20-F for the period ended Dec 31, 2024

- Company: [Lakefront Biotherapeutics NV](/companies/lkft.md) (CIK 1421876)
- Form: 20-F
- Filed: 2025-03-27
- Accepted by EDGAR: Mar 27, 2025, 16:00 ET
- Period: 2024-12-31
- Accession: 0001558370-25-003806
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1421876/000155837025003806/glpg-20241231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1421876/000155837025003806/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2024-01-01 to 2024-12-31 | EUR 275.6m | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2024-01-01 to 2024-12-31 | EUR 34.9m | ifrs-full:CostOfSales |
| Operating income | 12 months, 2024-01-01 to 2024-12-31 | −EUR 188.3m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2024-01-01 to 2024-12-31 | −EUR 1.8m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2024-01-01 to 2024-12-31 | EUR 74.1m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2024-01-01 to 2024-12-31 | EUR 1.12 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2024-01-01 to 2024-12-31 | EUR 1.12 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2024-01-01 to 2024-12-31 | −EUR 320.0m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-01-01 to 2024-12-31 | EUR 16.7m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2024-12-31 | $40.3m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2024-12-31 | EUR 3.34bn | ifrs-full:CurrentAssets |
| Total assets | at 2024-12-31 | EUR 4.14bn | ifrs-full:Assets |
| Current liabilities | at 2024-12-31 | EUR 335.1m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2024-12-31 | EUR 1.24bn | ifrs-full:Liabilities |
| Shareholders' equity | at 2024-12-31 | EUR 2.90bn | ifrs-full:Equity |
| Shares outstanding | at 2024-12-31 | 65,897,071 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1421876/000155837025003806/glpg-20241231x20f.htm

Filed Mar 27, 2025.
Source: SEC EDGAR, the filing index for accession 0001558370-25-003806. Last ingested by Listed: Nov 4, 2026, 10:00 ET. No prices; not investment advice.